HDAC Inhibitors Target IRS4 to Enhance Anti-AR Therapy in AR-Positive Triple-Negative Breast Cancer

A combination of an androgen receptor (AR) inhibitor and a selective histone deacetylase inhibitor was used to treat AR‑positive TNBC cell lines, and a synergistic effect of these drugs was observed.